Showing 721-730 of 2293 results for "".
- 2024 Lifetime Achievement Award in Alzheimer’s Disease Therapeutic Research Presented to Lars Lannfelt, MD, PhDhttps://practicalneurology.com/news/2024-lifetime-achievement-award-in-alzheimers-disease-therapeutic-research-presented-to-lars-lannfelt-md-phd/2470618/Lars Lannfelt, MD, PhD has been recognized as the recipient of the 2024 Lifetime Achievement Award in Alzheimer’s Disease Therapeutic Research at the 17th annual Clinical Trials on Alzheimer’s Disease (CTAD) conference. Dr. Lannfelt was selected based on his pioneering work in Alzheim
- UCSF Professor Bruce Ovbiagele, MD Recognized with Scientific Breakthrough Award at AAN 2024https://practicalneurology.com/news/ucsf-professor-bruce-ovbiagele-md-recognized-with-scientific-breakthrough-award-at-aan-2024/2470442/This year, the American Brain Foundation (ABF) awarded Bruce Ovbiagele, MD, MAS, FAAN the annual Scientific Breakthrough Award. Dr Ovbiagele, a Professor of Neurology at University of California (UC) San Francisco and Associate Dean of the San Francisco Veterans Affairs (VA) Healthcare Syste
- Higher Relapse and Adverse Event Rates Reported with Generic Fingolimod vs Gilenyahttps://practicalneurology.com/news/higher-relapse-and-adverse-event-rates-reported-with-generic-fingolimod-vs-gilenya/2474993/A retrospective study presented at the 2025 Annual Meeting of The Consortium of Multiple Sclerosis Centers examined clinical and radiologic outcomes in patients with multiple sclerosis (MS) who transitioned from branded Gilenya (Novartis; East Hanover, NJ) treatment to generic fingolimod. The ana
- Long-Term Data Reveal Ocrevus Comparable to Tysabri Tx in Effectiveness, Safety Outcomeshttps://practicalneurology.com/news/long-term-data-reveals-ocrevus-comparable-to-tysabri-tx-in-effectiveness-safety-outcomes/2470583/Treatment with Ocrevus (ocrelizumab; Genentech, South San Francisco, CA) for people with multiple sclerosis (MS) showed comparable effectiveness, safety, and treatment persistence to treatment with Tysabri (natalizumab; Biogen, Cambridge, MA) over a 5-year observation period. The results of a lon
- Fumarates and S1Ps Have Comparable Effectiveness in Black Patients with Relapsing Multiple Sclerosishttps://practicalneurology.com/news/fumarates-and-s1ps-have-comparable-effectiveness-in-black-patients-with-relapsing-multiple-sclerosis-1/2470489/Fumarates and sphingosine-1-phosphate receptor modulators (S1Ps), 2 types of disease-modifying therapy (DMT), were shown to have comparable effectiveness when used to treat Black patients with relapsing multiple sclerosis (MS). The findings, which were presented at the 24th Annual Meeting of the
- Barancik Prize Awarded to Sergio E. Baranzini, PhD at ACTRIMS 2024https://practicalneurology.com/news/barancik-prize-awarded-to-sergio-e-baranzini-phd-at-actrims-2024/2470413/This year, the National Multiple Sclerosis Society has awarded Sergio E. Baranzini, PhD the prestigious Barancik Prize for Innovation in Multiple Sclerosis (MS) Research. Professor Baranzini is a geneticist, neuroimmunologist, and data scientist at the University of California, San Francisco (UCS
- In Utero Exposure to Ocrevus Not Associated with Elevated Adverse Outcomes in Pregnancyhttps://practicalneurology.com/news/in-utero-exposure-to-ocrevus-not-associated-with-elevated-adverse-outcomes-in-pregnancy/2470314/In a study of the largest available dataset for pregnancy outcomes for an anti-CD20 monoclonal antibody therapy, in utero exposure to Ocrevus (ocrelizumab; Genentech, South San Francisco, CA), a medication used to treat multiple sclerosis (MS), was not associated with an elevated risk of preterm
- Vaccinations Not Associated with Multiple Sclerosis Flare-ups According to New Studyhttps://practicalneurology.com/news/vaccinations-not-associated-with-multiple-sclerosis-flare-ups-according-to-new-study/2470300/According to results from a nationwide French study published in JAMA Neurology, there was no association between vaccinations and incidence of severe multiple sclerosis (MS) flare-ups requiring hospitalization. The findings were consistent regardless of age range, whether the participan
- Researchers Confirm 4 Genes Associated with Increased Risk of Developing PMLhttps://practicalneurology.com/news/researchers-confirm-4-genes-associated-with-an-increased-risk-of-developing-pml-researchers-confirm-4-genes-associated-with-an-increased-risk-of-developing-pml/2470291/Researchers have identified 4 genes associated with an increased risk of developing progressive multifocal leukoencephalopathy (PML) in patients taking 99 different PML-linked drugs for a variety of conditions, including multiple sclerosis (MS), blood cancers, and rheumatoid arthritis. This study
- With High Costs and Similar Benefits, Use of New Neurologic Drugs Is Lowhttps://practicalneurology.com/news/with-high-costs-and-similar-benefits-use-of-new-neurologic-drugs-is-low/2470073/A study published in Neurology showed that a number of new neurologic medications for diseases such as multiple sclerosis (MS), Parkinson disease (PD), and migraine have received Food and Drug Administration (FDA) approval, but only a small percentage of patients are being treated with t